When stratified by tumor type, S100P overexpression predicted poor OS in cholangiocarcinoma (HR=2.14, 95% CI: 1.30-3.50, P=0.003) and hepatocellular carcinoma (HR=1.91, 95% CI: 1.22-2.99, P =0.005) but not in gastric cancer (HR=0.97, 95% CI: 0.65-1.45, P=0.872), colorectal cancer (HR=1.18, 95% CI: 0.32-4.41, P=0.807), gallbladder cancer (HR=1.40, 95% CI: 0.84-2.34, P=0.198), and pancreatic cancer (HR=1.92, 95% CI: 0.99-3.72, P=0.053). Here, S100P is linked to pancreatic neoplasm.